Express News | Zura Bio Ltd - Trial Is Expected to Initiate in Q4 2024
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults With Systemic Sclerosis
H.C. Wainwright Maintains Zura Bio(ZURA.US) With Hold Rating, Maintains Target Price $5
Cautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial Uncertainty
Chardan Capital Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $12
Guggenheim Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $15
